Late-onset Fabry disease: the cardiac sequela. Issue 6 (9th June 2022)

• Record Type: Journal Article
• Authors: Tremblay, John; Kim, Samuel; Philbin, Edward; Beers, Kelly; Lightle, Andrea; Belov, Dmitri
• Is Part Of: BMJ case reports. Volume 15:Issue 6(2022)
• Publication Date: 2022-06-09
• Subjects: Cardiovascular system -- Heart failure -- Arrhythmias; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2021-247917
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : We describe a patient with Fabry disease (FD) who initially presented with atrial fibrillation without left ventricular hypertrophy (LVH) 14 years before being correctly diagnosed with FD. In the interim, he survived a myocardial infarction complicated by ventricular fibrillation, and his severe LVH was misdiagnosed as sarcomeric hypertrophic cardiomyopathy. In the following 4 years, he developed proteinuric kidney disease, neuropathy, sensorineural hearing loss and gastrointestinal symptoms. The patient was eventually readmitted for an overt heart failure (HF) exacerbation and was seen by an HF cardiologist. The constellation of systemic findings led to further diagnostic testing, including an endomyocardial biopsy, tests to determine alpha-galactosidase A enzyme activity and α-galactosidase A gene (GLA) analysis. The results of the patient's tests were consistent with FD and he was started on enzyme replacement therapy. To our knowledge, this is the first detailed description of a late-onset phenotype of FD with c.146 G>C GLA variant. In addition, this case serves as a potent reminder to pay meticulous attention to 'red flags' accompanying LVH.